XOLAIR® (omalizumab) prescribing information (external link)
This page includes promotional content created and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned.
Respiratory and inflammation
XOLAIR® (omalizumab)
Image
Dosage information*
Dosage information*
PDF
Video
6 mins 29 secs
Instruction video for Xolair injection – Patients
Video
6 mins 47 secs
Instructions for using the Xolair autoinjector
Self-administration starter kit (1): The essentials
Self-administration starter kit (1): The essentials
Web Link
Self-administration starter kit (2): A guide to self injection
Self-administration starter kit (2): A guide to self injection
Web Link
Self-administration starter kit (3): Things for you to fill in
Self-administration starter kit (3): Things for you to fill in
Web Link
Self-administration starter kit (4): Important information
Self-administration starter kit (4): Important information
Web Link
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
